HER2 Support Group Forums - View Single Post

Lani · 06-12-2013, 05:09 PM

WAS AT ASCO AND heard the second talk but not the first

THE good news is that you are not metastatic...the other good news is that they are finding more effective drugs (although immunotherapy sounds more promising in the long run)

The problem is your tumor is rare and they are finding it hard to recruit enough patients for their trials. Let's hope you don't need to be on them.

News and Insights from Memorial Sloan-Kettering
IN THE CLINIC
Memorial Sloan-Kettering Researchers Report on Major Advances in the Treatment of Metastatic Eye and Skin Melanoma
1 commentBy Media Staff | Monday, June 3, 2013

Medical oncologists Jedd Wolchok and Richard Carvajal
Memorial Sloan-Kettering clinician-researchers presented new research on treatments for two different types of melanoma this weekend as part of the 49th annual meeting of the American Society of Clinical Oncology (ASCO). The studies are shedding light on new therapies for advanced uveal melanoma, a rare cancer of the eye, and advanced skin melanoma – two cancers that have always been difficult to treat.

The first study showed that the experimental drug selumetinib is the first therapy able to improve progression-free survival and shrink tumors in patients with advanced uveal melanoma. If confirmed in another clinical trial, the findings might change the way this cancer has been treated for decades.

The second study, which was also published on June 2 in The New England Journal of Medicine, found that more than half of patients with advanced skin melanoma experienced tumor shrinkage of more than 80 percent when given the combination of the immunotherapy drug ipilimumab (YervoyTM) and the investigational antibody drug nivolumab, suggesting that these two drugs may work better together than on their own.

Targeted Drug for Uveal Melanoma
On Saturday, June 1, medical oncologist Richard Carvajal presented findings from a study testing the experimental drug selumetinib as a treatment for patients with metastatic uveal melanoma. This treatment more than doubled the time to progression when compared with chemotherapy. Many patients receiving selumetinib experienced tumor shrinkage, making selumetinib the first systemic therapy ever to benefit patients with this cancer. The findings are potentially practice changing for a disease that has previously had no known effective therapy.

In the Phase II trial, researchers randomly assigned 47 patients with metastatic uveal melanoma to receive selumetinib and 49 patients to receive the current standard therapy, temozolomide. In the selumetinib group, 50 percent of patients experienced tumor shrinkage, with 15 percent achieving major shrinkage.

In comparison, no patients in the temozolomide group achieved significant tumor shrinkage. However, patients whose disease worsened while on temozolomide were able to begin taking selumetinib.

In addition, selumetinib was shown to control tumor growth more than twice as long as temozolomide – for nearly 16 weeks versus seven weeks. Side effects caused by selumetinib were managed by modifying the dosage if needed.

“This is the first randomized study to show that a systemic therapy can provide significant benefit to advanced uveal melanoma patients, who have always had extremely limited treatment options,” says Dr. Carvajal, who is currently planning a confirmatory international, randomized trial for selumetinib led by Memorial Sloan-Kettering.

“Confirming these results could form a foundation for new drug combinations that would maximize selumetinib’s effect, offering a whole new way to treat this historically untreatable disease,” he adds.

Although uveal melanoma is rare – there are only 2,500 cases diagnosed in the United States each year – about half of patients diagnosed eventually develop metastatic disease. The survival time for patients with advanced disease has held steady at nine months to a year for decades. There is currently no drug approved specifically for treatment of this cancer, which does not respond to the drugs given to patients with skin melanoma.

Dr. Carvajal and his team decided to test selumetinib because it blocks the activity of the MEK protein, a key component of a cellular process called the MAPK pathway. This pathway is activated by mutations in the genes Gnaq and Gna11 that occur in more than 85 percent of patients with uveal melanoma, inducing the growth and progression of tumors. Nearly 85 percent of the patients in the trial had such mutations.

Read more about the trial in this story from Reuters.(don't know how to perpetuate link)

for you to appreciate how important this may be, the NCI had the following on their website, which is how I found the article:

News
Contact the NCI Office of Media Relations | RSS Feed
Posted: 06/04/2013
Find News Releases

NCI Cancer Center News
Targeted drug for uveal melanoma
Researchers from Memorial Sloan-Kettering Cancer Center presented findings at the annual meeting of the American Society for Clinical Oncology from a study testing the experimental drug selumetinib as a treatment for patients with metastatic uveal melanoma. This treatment more than doubled the time to progression when compared with chemotherapy. Many patients receiving selumetinib experienced tumor shrinkage, making selumetinib the first systemic therapy ever to benefit patients with this cancer. The findings are potentially practice changing for a disease that has previously had no known effective therapy.

06-12-2013, 05:09 PM	#29
Lani Senior Member Join Date: Mar 2006 Posts: 4,778	Re: Met with Ocular Melanoma Oncologist WAS AT ASCO AND heard the second talk but not the first THE good news is that you are not metastatic...the other good news is that they are finding more effective drugs (although immunotherapy sounds more promising in the long run) The problem is your tumor is rare and they are finding it hard to recruit enough patients for their trials. Let's hope you don't need to be on them. News and Insights from Memorial Sloan-Kettering IN THE CLINIC Memorial Sloan-Kettering Researchers Report on Major Advances in the Treatment of Metastatic Eye and Skin Melanoma 1 commentBy Media Staff \| Monday, June 3, 2013 Medical oncologists Jedd Wolchok and Richard Carvajal Memorial Sloan-Kettering clinician-researchers presented new research on treatments for two different types of melanoma this weekend as part of the 49th annual meeting of the American Society of Clinical Oncology (ASCO). The studies are shedding light on new therapies for advanced uveal melanoma, a rare cancer of the eye, and advanced skin melanoma – two cancers that have always been difficult to treat. The first study showed that the experimental drug selumetinib is the first therapy able to improve progression-free survival and shrink tumors in patients with advanced uveal melanoma. If confirmed in another clinical trial, the findings might change the way this cancer has been treated for decades. The second study, which was also published on June 2 in The New England Journal of Medicine, found that more than half of patients with advanced skin melanoma experienced tumor shrinkage of more than 80 percent when given the combination of the immunotherapy drug ipilimumab (YervoyTM) and the investigational antibody drug nivolumab, suggesting that these two drugs may work better together than on their own. Targeted Drug for Uveal Melanoma On Saturday, June 1, medical oncologist Richard Carvajal presented findings from a study testing the experimental drug selumetinib as a treatment for patients with metastatic uveal melanoma. This treatment more than doubled the time to progression when compared with chemotherapy. Many patients receiving selumetinib experienced tumor shrinkage, making selumetinib the first systemic therapy ever to benefit patients with this cancer. The findings are potentially practice changing for a disease that has previously had no known effective therapy. In the Phase II trial, researchers randomly assigned 47 patients with metastatic uveal melanoma to receive selumetinib and 49 patients to receive the current standard therapy, temozolomide. In the selumetinib group, 50 percent of patients experienced tumor shrinkage, with 15 percent achieving major shrinkage. In comparison, no patients in the temozolomide group achieved significant tumor shrinkage. However, patients whose disease worsened while on temozolomide were able to begin taking selumetinib. In addition, selumetinib was shown to control tumor growth more than twice as long as temozolomide – for nearly 16 weeks versus seven weeks. Side effects caused by selumetinib were managed by modifying the dosage if needed. “This is the first randomized study to show that a systemic therapy can provide significant benefit to advanced uveal melanoma patients, who have always had extremely limited treatment options,” says Dr. Carvajal, who is currently planning a confirmatory international, randomized trial for selumetinib led by Memorial Sloan-Kettering. “Confirming these results could form a foundation for new drug combinations that would maximize selumetinib’s effect, offering a whole new way to treat this historically untreatable disease,” he adds. Although uveal melanoma is rare – there are only 2,500 cases diagnosed in the United States each year – about half of patients diagnosed eventually develop metastatic disease. The survival time for patients with advanced disease has held steady at nine months to a year for decades. There is currently no drug approved specifically for treatment of this cancer, which does not respond to the drugs given to patients with skin melanoma. Dr. Carvajal and his team decided to test selumetinib because it blocks the activity of the MEK protein, a key component of a cellular process called the MAPK pathway. This pathway is activated by mutations in the genes Gnaq and Gna11 that occur in more than 85 percent of patients with uveal melanoma, inducing the growth and progression of tumors. Nearly 85 percent of the patients in the trial had such mutations. Read more about the trial in this story from Reuters.(don't know how to perpetuate link) for you to appreciate how important this may be, the NCI had the following on their website, which is how I found the article: News Contact the NCI Office of Media Relations \| RSS Feed Posted: 06/04/2013 Find News Releases NCI Cancer Center News Targeted drug for uveal melanoma Researchers from Memorial Sloan-Kettering Cancer Center presented findings at the annual meeting of the American Society for Clinical Oncology from a study testing the experimental drug selumetinib as a treatment for patients with metastatic uveal melanoma. This treatment more than doubled the time to progression when compared with chemotherapy. Many patients receiving selumetinib experienced tumor shrinkage, making selumetinib the first systemic therapy ever to benefit patients with this cancer. The findings are potentially practice changing for a disease that has previously had no known effective therapy.